These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28948436)

  • 21. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
    Su J; Liu T; Li S; Zhao Y; Kuang Y
    J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
    [No Abstract]   [Full Text] [Related]  

  • 22. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
    Yousefi M; Nahvijou A; Sari AA; Ameri H
    Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
    Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
    J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of FACT- and EQ-5D-based utility scores in cancer.
    Pickard AS; Ray S; Ganguli A; Cella D
    Value Health; 2012; 15(2):305-11. PubMed ID: 22433762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping MacNew Heart Disease Quality of Life Questionnaire onto country-specific EQ-5D-5L utility scores: a comparison of traditional regression models with a machine learning technique.
    Gao L; Luo W; Tonmukayakul U; Moodie M; Chen G
    Eur J Health Econ; 2021 Mar; 22(2):341-350. PubMed ID: 33438134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.
    Gandhi M; Ang M; Teo K; Wong CW; Wei YC; Tan RL; Janssen MF; Luo N
    Patient; 2019 Aug; 12(4):383-392. PubMed ID: 30607809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
    Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping study of papillary thyroid carcinoma in China: Predicting EQ-5D-5L utility values from FACT-H&N.
    Huang D; Peng J; Chen N; Yang Q; Jiang L
    Front Public Health; 2023; 11():1076879. PubMed ID: 36908441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson's disease population sample.
    García-Gordillo M; del Pozo-Cruz B; Adsuar JC; Sánchez-Martínez FI; Abellán-Perpiñán JM
    Qual Life Res; 2014 May; 23(4):1315-26. PubMed ID: 24258254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Developing mapping algorithms to predict EQ-5D health utility values from Bath Ankylosing Spondylitis Disease Activity Index and Bath Ankylosing Spondylitis Functional Index among patients with Ankylosing Spondylitis.
    Yu L; Yang H; Lu L; Fang Y; Zhang X; Li S; Li C
    Health Qual Life Outcomes; 2024 Aug; 22(1):61. PubMed ID: 39113080
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8).
    Tsiachristas A; Potter CM; Rocks S; Peters M; Cundell M; McShane R; Batchelder L; Fox D; Forder JE; Jones K; Waite F; Freeman D; Fitzpatrick R
    Health Qual Life Outcomes; 2020 Aug; 18(1):279. PubMed ID: 32795317
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.
    Xie S; Wu J; Chen G
    Eur J Health Econ; 2024 Feb; 25(1):7-19. PubMed ID: 36709458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of EQ-5D-5L and SPVU-5D for measuring quality of life in patients with venous leg ulcers in an Australian setting.
    Cheng Q; Kularatna S; Lee XJ; Graves N; Pacella RE
    Qual Life Res; 2019 Jul; 28(7):1903-1911. PubMed ID: 30778889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
    Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
    Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
    Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
    Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.
    Vilsbøll AW; Kragh N; Hahn-Pedersen J; Jensen CE
    Qual Life Res; 2020 Sep; 29(9):2529-2539. PubMed ID: 32297132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychometric Properties of EQ-5D-5L Scoring Algorithms for the United Kingdom in Metastatic Merkel Cell Carcinoma.
    Bharmal M; Hunger M; Schlichting M
    Value Health; 2019 Oct; 22(10):1170-1177. PubMed ID: 31563260
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicting health-related quality of life (EQ-5D-5 L) and capability wellbeing (ICECAP-A) in the context of opiate dependence using routine clinical outcome measures: CORE-OM, LDQ and TOP.
    Peak J; Goranitis I; Day E; Copello A; Freemantle N; Frew E
    Health Qual Life Outcomes; 2018 May; 16(1):106. PubMed ID: 29843726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.